Merckonomics

I have received a few snotty emails the last couple of days regarding my commentary about Bionomics (ASX : BNO). Fair enough. Yes, I accepted face-value information about chemical composition instead of trawling patents, and yes I am anal-retentive about “mechanism of action” details for CNS drugs. So shoot me. At least someone is asking questions. Amidst the…

Note to Prima Biomed Shareholders…

By now, the proxy forms are in and the majority of shareholders will have already cast their vote regarding the five resolutions for the EGM meeting on Friday. Obviously a show of hands in a shareholder meeting is not going to be the deciding factor here. I have been unabashedly clear in my position that…

The Pink Panther Strikes Again

The only true certainty in life is that history will repeat itself, just like that throaty little Shirley Bassey number. In case you haven’t noticed by now I really love what I do – mainly because when history repeats itself, especially the stupid kind, I am there and ready for sarcastic commentary. Like the deranged curator…

Clinical Trial Communication Matters

Over the past few months I have poked several companies in the eye for the appalling quality of their clinical communication. I have specifically paid attention to Novogen (ASX : NRT), Benitec (ASX : BLT), Regeneus (ASX : RGS) and a few others. It is my position is that there is a consistently low quality and sensationalist ethos…

Almost Antisensible : Correction

Normally I pride myself on being reasonably thorough when I comment on a company. In this instance (my prior post), I was sloppy and I apologise, I did not look closely at the other ASX disclosures around the deal and missed the Appendix 3B filing. I will not make excuses but I figure if paid-up…